Prescott Group Capital Management L.L.C. Has $4.93 Million Stake in Emergent Biosolutions Inc. $EBS

Prescott Group Capital Management L.L.C. increased its position in Emergent Biosolutions Inc. (NYSE:EBS) by 23.1% during the second quarter, Holdings Channel.com reports. The firm owned 772,771 shares of the biopharmaceutical company’s stock after buying an additional 145,100 shares during the quarter. Prescott Group Capital Management L.L.C.’s holdings in Emergent Biosolutions were worth $4,930,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of EBS. Acadian Asset Management LLC lifted its stake in shares of Emergent Biosolutions by 17.0% in the second quarter. Acadian Asset Management LLC now owns 974,590 shares of the biopharmaceutical company’s stock valued at $6,216,000 after buying an additional 141,274 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Emergent Biosolutions by 5.9% in the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 986,673 shares of the biopharmaceutical company’s stock worth $6,295,000 after purchasing an additional 55,046 shares during the last quarter. Hussman Strategic Advisors Inc. grew its holdings in Emergent Biosolutions by 400.0% during the second quarter. Hussman Strategic Advisors Inc. now owns 105,000 shares of the biopharmaceutical company’s stock worth $670,000 after buying an additional 84,000 shares in the last quarter. Wolverine Asset Management LLC grew its holdings in Emergent Biosolutions by 28.3% during the second quarter. Wolverine Asset Management LLC now owns 174,933 shares of the biopharmaceutical company’s stock worth $1,116,000 after buying an additional 38,600 shares in the last quarter. Finally, Stratos Wealth Partners LTD. bought a new stake in shares of Emergent Biosolutions in the 2nd quarter worth $156,000. Institutional investors own 78.40% of the company’s stock.

Wall Street Analysts Forecast Growth

EBS has been the subject of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Emergent Biosolutions in a research report on Wednesday, October 8th. Zacks Research upgraded Emergent Biosolutions to a “hold” rating in a report on Friday, October 24th. Wall Street Zen raised Emergent Biosolutions from a “buy” rating to a “strong-buy” rating in a research report on Sunday. Finally, HC Wainwright restated a “buy” rating and set a $15.00 price objective on shares of Emergent Biosolutions in a report on Wednesday, September 3rd. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $15.00.

Insider Buying and Selling

In related news, Director Kathryn C. Zoon sold 7,086 shares of the business’s stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $8.87, for a total transaction of $62,852.82. Following the completion of the transaction, the director owned 71,799 shares of the company’s stock, valued at approximately $636,857.13. The trade was a 8.98% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Donald W. Degolyer sold 7,844 shares of the firm’s stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $8.65, for a total transaction of $67,850.60. Following the completion of the transaction, the director directly owned 137,659 shares of the company’s stock, valued at approximately $1,190,750.35. The trade was a 5.39% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 45,538 shares of company stock valued at $436,783. Corporate insiders own 1.20% of the company’s stock.

Emergent Biosolutions Price Performance

EBS opened at $10.11 on Friday. The company has a market capitalization of $530.71 million, a price-to-earnings ratio of 7.77 and a beta of 2.06. The company has a quick ratio of 3.00, a current ratio of 5.66 and a debt-to-equity ratio of 1.25. The firm has a 50-day moving average price of $9.09 and a 200-day moving average price of $7.60. Emergent Biosolutions Inc. has a twelve month low of $4.02 and a twelve month high of $13.41.

Emergent Biosolutions (NYSE:EBS) last released its quarterly earnings data on Tuesday, January 9th. The biopharmaceutical company reported ($1.27) EPS for the quarter. Emergent Biosolutions had a return on equity of 21.43% and a net margin of 9.62%.The business had revenue of $222.50 million during the quarter. Emergent Biosolutions has set its FY 2023 guidance at EPS. Equities analysts expect that Emergent Biosolutions Inc. will post -0.63 EPS for the current year.

Emergent Biosolutions Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.